Protocol Ledger

NCT05485961 · Phase II/III · RECRUITING

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Interventional Phase II/III clinical trial protocol NCT05485961 sponsored by CSL Behring in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-27 Enrollment: 3,110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05485961
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05485961
Protocol FieldVerified Registry Value
NCT IdentifierNCT05485961
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,110 participants (ESTIMATED)
Registered Start Date2024-04-27
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI